Latest news with #IndocoRemedies
Business Standard
24-07-2025
- Business
- Business Standard
Indoco Remedies reports consolidated net loss of Rs 35.79 crore in the June 2025 quarter
Sales rise 1.13% to Rs 429.08 crore Net loss of Indoco Remedies reported to Rs 35.79 crore in the quarter ended June 2025 as against net profit of Rs 2.62 crore during the previous quarter ended June 2024. Sales rose 1.13% to Rs 429.08 crore in the quarter ended June 2025 as against Rs 424.29 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 429.08424.29 1 OPM % 4.0911.26 - PBDT -6.9634.49 PL PBT -36.666.97 PL NP -35.792.62 PL
&w=3840&q=100)
Business Standard
24-07-2025
- Business
- Business Standard
Indoco Remedies rises 6% on EU GMP certificate, trims gains after Q1 show
Indoco Remedies share price: Shares of pharmaceutical company Indoco Remedies were in focus on Thursday, July 24, 2025, with the scrip rising as much as 5.99 per cent to an intraday high of ₹328.65 per share. By 12:41 PM, Indoco Remedies shares had pared some gains, and were trading 4.18 per cent higher at ₹323 after weak Q1 results. In comparison, the BSE Sensex was down 0.64 per cent at 82,198.32 levels. Indoco Remedies gets EU GMP Compliance certificate Earlier in the day, Indoco Remedies had announced that it has received a Certificate of EU Good Manufacturing Practices (GMP) Compliance from the European Health Authorities for its sterile drug product manufacturing facility at Goa Plant II. "The EU GMP certification issued by the European Health Authorities confirms that the site complies with the Good Manufacturing Practice requirements," the company said. Aditi Panandikar, managing director, Indoco Remedies, said, 'This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies. We remain fully committed to adhering to cGMP standards and consistently delivering quality products to customers and patients worldwide.' Indoco Remedies Q1 results Indoco Remedies posted a disappointing set of numbers for the June quarter of financial year 2026 (Q1FY26). Indoco Remedies reported a net loss of ₹35.6 crore in Q1FY26, compared to a profit of ₹2.6 crore in the same period last year (Q1FY25). Revenue rose marginally (1.5 per cent) year-on-year (Y-o-Y) to ₹438 crore in the June quarter of FY26, from ₹431.5 crore in the June quarter of FY25. Operational performance took a major hit. Ebitda, also known as operating performance, declined 63.3 per cent Y-o-Y to ₹17.5 crore, as against ₹47.8 crore in the same quarter a year ago, while margins contracted to 4 per cent in Q1FY26, from 11.1 per cent in Q1FY25. About Indoco Remedies Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a strong global footprint. With a turnover of $180 million and a workforce of over 6,000 employees – including more than 400 skilled scientists and field staff – the company is built on a foundation of scientific excellence and operational strength. The company operates 11 manufacturing facilities, comprising seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs), supported by a state-of-the-art R&D center and a contract research organization (CRO). These facilities are approved by key global regulatory bodies such as the USFDA and UK-MHRA, enabling Indoco to cater to both domestic and international markets. The company commands a strong presence in the Indian market with over 106 million prescriptions generated annually by more than 2,40,000 doctors across various specialties. Indoco has 10 domestic marketing divisions and a robust brand portfolio spanning multiple therapeutic segments including gastrointestinal, respiratory, anti-infectives, ophthalmology, cardiovascular, pain management, and more. Leading brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Cital. On the global front, Indoco Remedies has forged strategic partnerships with several major generic companies, further strengthening its position in regulated and emerging markets alike.
Business Upturn
24-07-2025
- Business
- Business Upturn
Indoco Remedies Q1 Results: Revenue flat at Rs 42 crore, Net loss of Rs 3.6 crore
Indoco Remedies Limited reported a net loss of Rs 3.64 crore for the quarter ended June 30, 2025 (Q1FY26), compared to a profit of Rs 1.82 crore in the corresponding quarter last year. This marks the second consecutive quarter of losses, as the company had posted a Rs 4.13 crore loss in Q4FY25. Revenue from operations in Q1FY26 stood at Rs 42.91 crore, up marginally from Rs 42.43 crore reported in Q1FY25. Including other operating income of Rs 8.81 crore, total income for the quarter reached Rs 43.79 crore. With additional other income of Rs 1.63 crore, total income was Rs 43.95 crore, a slight increase from Rs 43.25 crore YoY. Despite the revenue uptick, expenses surged significantly to Rs 47.62 crore in Q1FY26, up from Rs 42.56 crore in the same quarter last year. Key cost drivers included higher raw material costs (Rs 10.55 crore), employee expenses (Rs 10.7 crore), and other operating expenses (Rs 15.67 crore). Finance costs also increased to Rs 2.61 crore from Rs 1.43 crore YoY. The company reported a loss before tax of Rs 3.66 crore, with no exceptional items during the quarter. Tax expenses for the quarter were negligible, resulting in a final net loss of Rs 3.64 crore. The results highlight the pressure Indoco Remedies is facing despite stable revenues, with rising costs weighing heavily on profitability. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Standard
24-07-2025
- Business
- Business Standard
Indoco Remedies edges higher after receiving EU GMP certificate for Goa-based manufacturing facility
Indoco Remedies rose 2.35% to Rs 317.35 after the company announced the receipt of certificate for EU Good Manufacturing Practices (GMP) compliance from the European Health Authorities for its sterile drug product manufacturing facility Goa Plant II. The said unit is located at L32, 33 and 34, Verna Industrial Estate, South Goa. The EU GMP certification issued by the European Health Authorities confirms that the site complies with the good manufacturing practice requirements. Aditi Panandikar, managing director, Indoco Remedies, said: "This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies. We remain fully committed to adhering to cGMP standards and consistently delivering quality products to customers and patients worldwide." Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company had reported a consolidated net loss of Rs 40.39 crore in the quarter ended March 2025 as against net profit of Rs 22.70 crore during the previous quarter ended March 2024. Sales declined by 12.57% to Rs 383.89 crore in Q4 FY25 over Q4 FY24.
Time of India
03-06-2025
- Business
- Time of India
Initiative appointed as Media Agency on Record for Sensodent
Initiative has been appointed as the media agency on record for Sensodent , a specialised oral care brand from Indoco Remedies , a Mumbai-based pharmaceutical company. As Sensodent gears up to strengthen its leadership in the oral sensitivity segment, Initiative will lead the brand's media strategy, planning, and deployment across platforms—focusing on driving awareness, trials, and brand relevance at scale. The media mandate was awarded following a multi-agency pitch process . Commenting on this development, Aditi Panandikar, managing director, Indoco Remedies said, 'Our brand Sensodent is the first to go OTC and over the year has evolved into the next orbit. We are thrilled to work together with Initiative and are looking forward to see our brand soaring newer heights.' Dhirendra Singh, executive vice president and head – Mumbai, Initiative, said, "Sensodent K is a high-potential brand in a growing yet underpenetrated category. We're excited to partner with Indoco Remedies to architect a media approach that drives performance, builds cultural relevance, and connects meaningfully with consumers across India." Speaking on the partnership, Vaishali Verma, chief executive officer, Initiative India, said, "We welcome Sensodent into the Initiative family. We look forward to a strong partnership focused on driving brand success and creating meaningful work."
